We are live on
!
Find out more
Frazier Life Sciences Management Portfolio holdings
AUM
$4.59B
Turnover
20.45%
1-Year Est. Return
237.58%
This Fund
S&P 500
This Quarter
Est. Return
-3.63%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.14B
AUM Growth
-$232M
(-9.8%)
Cap. Flow
-$62.6M
Cap. Flow
% of AUM
-2.93%
Top 10 Holdings %
Top 10 Hldgs %
61.97%
Holding
57
New
7
Increased
13
Reduced
4
Closed
8
Avg Time Held
1.3
years
Top 10 Avg Time Held
1.3
years
Top 20 Avg Time Held
1.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Erasca
ERAS
|
+$35M |
| 2 |
Disc Medicine
IRON
|
+$33M |
| 3 |
AnaptysBio
ANAB
|
+$29.5M |
| 4 |
Savara
SVRA
|
+$18.5M |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
+$18.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alpine Immune Sciences Inc
ALPN
|
+$124M |
| 2 |
Apellis Pharmaceuticals
APLS
|
+$52M |
| 3 |
Jade Biosciences
JBIO
|
+$35.6M |
| 4 |
Structure Therapeutics
GPCR
|
+$27M |
| 5 |
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
+$22.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.8% |
| 2 | Miscellaneous | 0.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Trevi Therapeutics
TRVI
$1.73B
| $22M | 1.03% |
7,381,090
| – | – |
2022 Q2
8 quarters
|
|
27
Silence Therapeutics
SLN
$581M
| $21.8M | 1.02% |
1,148,591
| – | – |
2022 Q1
9 quarters
|
|
|
28
Ultragenyx Pharmaceutical
RARE
$1.5B
| $17.5M | 0.82% |
+425,000
| New | +$18.1M |
2024 Q2
0 quarters
|
|
29
Autolus Therapeutics
AUTL
$458M
| $16.1M | 0.75% |
4,623,324
| – | – |
2022 Q1
9 quarters
|
|
30
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $16.1M | 0.75% |
393,000
| – | – |
2022 Q1
9 quarters
|
|
31
Mereo BioPharma
MREO
$49.4M
| $15.8M | 0.74% |
+4,401,371
| New | +$14.3M |
2024 Q2
0 quarters
|
|
32
Immatics
IMTX
$1.09B
| $13.4M | 0.63% |
+1,152,456
| New | +$13M |
2024 Q2
0 quarters
|
|
33
Tyra Biosciences
TYRA
$1.31B
| $13.3M | 0.62% |
832,220
| – | – |
2022 Q1
9 quarters
|
|
34
MacroGenics
MGNX
$215M
| $12.8M | 0.6% |
3,010,727
+539,023
| +22% | +$5.25M |
2023 Q1
5 quarters
|
|
35
DELISTED
Applied Therapeutics
APLT
| $10.7M | 0.5% |
2,286,135
+333,278
| +17% | +$1.58M |
2024 Q1
1 quarter
|
|
36
Puma Biotechnology
PBYI
$543M
| $9.98M | 0.47% |
3,062,558
+246,264
| +9% | +$1.08M |
2024 Q1
1 quarter
|
|
37
DELISTED
89bio
ETNB
| $8.01M | 0.37% |
1,000,000
| – | – |
2023 Q4
2 quarters
|
|
38
DELISTED
Elevation Oncology
ELEV
| $7.99M | 0.37% |
+2,958,579
| New | +$11.1M |
2024 Q2
0 quarters
|
|
39
Cogent Biosciences
COGT
$5.12B
| $7.9M | 0.37% |
936,576
| – | – |
2022 Q1
9 quarters
|
|
40
Acadia Pharmaceuticals
ACAD
$3.4B
| $7.64M | 0.36% |
470,338
| – | – |
2022 Q3
7 quarters
|
|
41
Arvinas
ARVN
$468M
| $7.6M | 0.36% |
285,331
| – | – |
2022 Q1
9 quarters
|
|
42
DELISTED
Adverum Biotechnologies
ADVM
| $7.34M | 0.34% |
1,069,244
| – | – |
2024 Q1
1 quarter
|
|
43
Allogene Therapeutics
ALLO
$463M
| $6.68M | 0.31% |
2,867,750
| – | – |
2024 Q1
1 quarter
|
|
44
AN2 Therapeutics
ANTX
$136M
| $4.49M | 0.21% |
2,088,889
+700,000
| +50% | +$1.67M |
2023 Q3
3 quarters
|
|
45
NewAmsterdam Pharma Warrant
NAMSW
| $4.36M | 0.2% |
500,333
| – | – |
2022 Q4
6 quarters
|
|
46
Design Therapeutics
DSGN
$656M
| $4M | 0.19% |
+1,195,179
| New | +$4.66M |
2024 Q2
0 quarters
|
|
47
Immunocore
IMCR
$1.52B
| $3.69M | 0.17% |
+108,762
| New | +$5.55M |
2024 Q2
0 quarters
|
|
48
Metagenomi Therapeutics
MGX
$31.9M
| $1M | 0.05% |
245,692
-33,333
| -12% | -$229K |
2024 Q1
1 quarter
|
|
49
Aclaris Therapeutics
ACRS
$514M
| $291K | 0.01% |
264,377
| – | – |
2022 Q1
9 quarters
|
|
|
50
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-885,165
| Closed | -$52M | – |
|
Similar funds
BWA
TYCC
Frazier Life Sciences Management's Q2 2024 Portfolio in Review
As of Q2 2024, Frazier Life Sciences Management held 57 positions worth $2.14B, down 9.8% from $2.37B the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Frazier Life Sciences Management's Q2 2024 filing shows 7 new, 13 increased, 4 reduced and 8 closed positions. Its largest new stake was Erasca: 16,216,216 shares worth $38.3M. The largest sale was Alpine Immune Sciences Inc, an estimated $124M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.
- Frazier Life Sciences Management's largest Q2 2024 buy was Erasca: 16,216,216 shares worth $38.3M.
- Frazier Life Sciences Management added most to Disc Medicine in Q2 2024, an estimated $33M increase.
- Frazier Life Sciences Management's biggest Q2 2024 reduction was Merus, cutting an estimated $18.1M.
- Frazier Life Sciences Management fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $124M.
- Frazier Life Sciences Management's ten largest holdings make up 62% of its $2.14B portfolio in Q2 2024.
- Frazier Life Sciences Management opened 7 new positions and closed 8 in Q2 2024.
- Frazier Life Sciences Management's portfolio value fell 9.8% quarter-over-quarter to $2.14B.
Based on Frazier Life Sciences Management's 13F filing for Q2 2024, filed 15 Aug 2024.